Skip to main content
SpringerLink
Log in

A new complication of imatinib: a case report

  • Short Communication
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Imatinib mesylate is a potent competitive inhibitor of tyrosine kinase and is used in the management of chronic myeloid leukaemia and gastrointestinal stromal tumours (GIST). Various acute and long-term adverse events have been described following the use of imatinib, but there has not yet been a report of delayed wound disruption. We present a case of GIST developing wound disruption after primary healing during adjuvant imatinib therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol. 2003;21(23):4342–9.

    Article  CAS  Google Scholar 

  2. Blackstein ME. Risk assessment for tumour recurrence after surgical resection of localized primary gastrointestinal stromal tumour (GIST): North America intergroup phase III trial ACOSOG Z9001 [abstract]. In: ASCO gastrointestinal cancers symposium; 2010.

  3. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.

    Article  CAS  Google Scholar 

  4. National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): gastrointestinal stromal tumours (version 3.2012). Fort Washington: National Comprehensive Cancer Network®, Inc.; 2012.

  5. Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010;4:315–23.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Armed Forces Medical College, Pune, 411040, India

    Sushila Chauhan & Sunil Anand

Authors
  1. Sushila Chauhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunil Anand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunil Anand.

Ethics declarations

Informed consent

Informed written consent was obtained from the patient for the publication of this case report.

Conflict of interest

SC and SA have no conflicts of interest.

Funding

No specific funding was received.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chauhan, S., Anand, S. A new complication of imatinib: a case report. Drugs Ther Perspect 34, 590–592 (2018). https://doi.org/10.1007/s40267-018-0558-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0558-3

Search

Navigation